Şenol Demir

Şenol Demir

Auto-generated profile, based on publicly available information

Şenol Demir

Department of Medical Genetics, School of Medicine Marmara University Istanbul Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2024 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
EVEva Vanbelleghem
Eva Vanbelleghem
TDTim Van Damme
Tim Van Damme
ABAude Beyens
Aude Beyens
SSSofie Symoens
Sofie Symoens
Kathleen ClaesKathleen Claes
Kathleen Claes
BCBert Callewaert
Bert Callewaert

15 February 2022 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
EAEsra Arslan Ateş
Esra Arslan Ateş
CACeren Alavanda
Ceren Alavanda
ŞDŞenol Demir
Şenol Demir
CKCaglayan Keklikkiran
Caglayan Keklikkiran
WAWafi Attaallah
Wafi Attaallah
AGAhmet İlTer Güney
Ahmet İlTer Güney
Background: Familial adenomatous polyposis (OMIM #175100) and MUTYH-associated polyposis (OMIM #608456) are rare cancerprone disorders characterized by hundreds of adenomatous polyps in the colon and rectum, which have a high probability of malignant transformation. Attenuated familial adenomatous polyposis is a variant of familial adenomatous polyposis, which is a term used for the condition in which patients have less than 100 colorectal polyps. Germline heterozygous Adenomatous polyposis coli (APC) and biallelic MUTYH (mutY DNA glycosylase) pathogenic variations are responsible for familial adenomatous polyposis and MUTYH-associated polyposis respectively. The aim of this study is to discuss the clinical manifestations of patients having pathogenic APC and MUTYH variations. Methods: We included 27 probands who have more than 10 colonic polyps in this study. After evaluation of their clinical and family histories, the probands were screened for APC and MUTYH variations via next generation sequencing. The family members of the probands carrying pathogenic variations were screened via Sanger sequencing. Results: Among 27 probands, pathogenic APC and MUTYH variations were detected in 3 and 6 probands respectively. In the APC gene, 3 novel truncating variations (p.Leu360*, p.Leu1489Phefs*23, and p.Leu912*) were detected in 3 unrelated probands. In the MUTYH gene, only 2 distinct pathogenic variations were detected (p.Pro295Leu and p.Glu480del) in the homozygous or compound heterozygous state. Conclusion: In this study, molecular etiology was clarified in 9 familial polyposis patients. The p.Pro295Leu and p.Glu480del variations seem to be common in the Turkish population and may be considered as a first-step genetic test in Turkish familial polyposis patients showing autosomal recessive inheritance. However more studies are needed to reveal the exact frequency of these variations.

8 August 2024 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
CACeren Alavanda
Ceren Alavanda
ŞDŞenol Demir
Şenol Demir
SGSerçin Güven
Serçin Güven
MEMehmet Eltan
Mehmet Eltan
SESevgi Bilgiç Eltan
Sevgi Bilgiç Eltan
STSerap Turan
Serap Turan
Schimke Immuno-Osseous Dysplasia (SIOD) (MIM:242900) is an ultra-rare autosomal recessive pan-ethnic pleiotropic disease. Typical findings of this syndrome are steroid-resistant nephrotic syndrome, cellular immunodeficiency and spondyloepiphyseal dysplasia and facial dysmorphism. Biallelic variants in the SMARCAL1 gene cause SIOD. The five-and-half-year-old female patient was evaluated because of short stature, dysmorphism, hypercalcemia, hypophosphatemia and elevated FSH levels. Karyotype analysis and array-CGH testing were normal. Clinical Exome Sequencing was performed via next-generation sequencing to analyze genes associated with hypophosphatemia. No pathogenic variant was detected. The subsequent detection of proteinuria during her follow-up for cross-fused ectopic left kidney ultimately facilitated the diagnosis of SIOD, although no obvious spondyloepiphyseal dysplasia was detected. Re-analysis of CES revealed a novel homozygous c.2422_2427+9delinsA pathogenic variant in the SMARCAL1. One hundred twenty-five SIOD cases from 38 literature reporting SMARCAL1 gene pathogenic variants were reviewed to investigate whether hypercalcemia, hypophosphatemia and elevated FSH levels had been previously reported in SIOD patients. This review revealed that this was the first time these findings had been reported in a SIOD patient. This report expands not only the phenotypic but also genotypic spectrum of SIOD.

7 December 2025 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Verified
Journal Article
Closed access
MBMaggie R. Brand
Maggie R. Brand
EVEva Vanbelleghem
Eva Vanbelleghem
AKAlison C. Kay
Alison C. Kay
AGAnne Goriely
Anne Goriely
SDSenol Demir
Senol Demir
ALAngela E. Lin
Angela E. Lin

6 January 2025 in Turkish Journal of Hematology
Verified
Journal Article
Open access
ODOMER DOGRU
OMER DOGRU
CACeren Alavanda
Ceren Alavanda
ŞDŞenol Demir
Şenol Demir
AKAhmet Koç
Ahmet Koç
PAPınar Ata
Pınar Ata
This study aims to determine the genotypic characteristics of Hereditary Spherocytosis (HS) patients in Turkiye and to examine the correlation between genotype and phenotype. Herein we had 18 patients who were admitted to pediatric hematology outpatient clinic with hemolytic anemia, jaundice, cholelithiasis, and splenomegaly. According to the Eber's classification, the patients' clinical presentations were categorized as mild, moderate, and severe. The next-generation sequencing method was used to analyze single nucleotide and copy number variations in all genes associated with HS via clinical exome sequencing (CES). The relationship between the genes with detected variants and the clinical presentation in the patients was investigated. In total, 21 variants were detected in five HS-related genes. Twelve of them were previously reported variants, and nine of them were novel variants. Seven of them were pathogenic and two of them were classified as Variant of Uncertain Significance (VUS) according to the American College of Medical Genetics and Genomics (ACMG). Herein we have discussed the phenotypic effects of novel pathogenic variants in SPTA1, SPTB, ANK1, SLC4A1, and EPB42 genes. Patients with EPB42 and SLC4A1 gene pathogenic variants had less severe clinical findings compared to other gene variants according to Eber's classification. On the other hand, patients carrying pathogenic variants of SPTA1 and SPTB genes had more severe clinical presentation. Molecular diagnosis of HS is important for treatment, prediction of the clinical outcome, and appropriate genetic counseling. As a result, our study contributes to the genotype-phenotype distribution of HS by introducing novel variants to the literature.

4 February 2025 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
CACeren Alavanda
Ceren Alavanda
EAEsra Arslan Ateş
Esra Arslan Ateş
ŞDŞenol Demir
Şenol Demir
HPHamza Polat
Hamza Polat
OHOnur Hanoğlu
Onur Hanoğlu
BGBilgen Bilge Geçkinli
Bilgen Bilge Geçkinli